Canaan Partners β 2017 Investments
8 investments dated 2017 Β· listed companies and verified rows first Β· show all
Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.
AdTechFintechMarketing TechAtlanta, US
Scott Grimes(Executive Officer, Director)inLynne Laube(Executive Officer, Director)Kirk Somers(Executive Officer)David Evans(Executive Officer)
BoardJohn Klinck(Director)inMark Johnson(Director)in
Board seatJohn BalenΒ· per SEC Form D
Co-investorsBaroda VenturesKinetic Ventures, L.L.C.Next Coast VenturesSavano Capital PartnersHyperplane Venture CapitalPolaris Partners+1 more
Aeva develops FMCW-based 4D LiDAR sensors and perception software that detect velocity and range simultaneously, using silicon photonics to integrate LiDAR elements on a chip.
Enterprise SoftwareFintechHardwareMobility & TransportationSaaSSemiconductorsPalo Alto, US
SOROUSH SALEHIAN DARDASHTI(Executive Officer, Director)MINA REZK(Executive Officer, Director)Soroush Salehian(CEO and Cofounder)
BoardSHAHIN FARSHCHI(Director)Yuan Chen(Capital Allocator)inSimon Mahony(Investor)
Co-investorsLux CapitalNext47Socii Capital
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)
BoardAlan E. Walts(Director)in
Board seatColleen CuffaroΒ· per SEC Form D
Co-investorsPfizer VenturesAdvent Life SciencesNextech InvestOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more
Engine by Gen (formerly Even Financial) operates an embedded finance marketplace platform that matches consumers with real-time, personalized financial product recommendations from a network of providers across mobile apps, websites, and other touchpoints.
B2B MarketplacesFintechMarketing TechSaaSBrooklyn, US
Phill Rosen(Founder & CEO)Ian Rosen(Executive Officer, Director)Jarid Maged(Executive Officer, Director)
Board seatBrendan DickinsonΒ· per SEC Form D
Co-investorsAAF Management Ltd.Conversion CapitalF-Prime CapitalGreatPoint VenturesMassMutual VenturesValuestream Ventures+4 more
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.
HealthtechMedical DevicesLexington, US
Carl Vause(Executive Officer, Director)Mira Sahney(Executive Officer, Director)David Myung(Director)
BoardMichael Hawkins(Director)William Harrington(Director)in
Board seatWende HuttonΒ· per SEC Form D
Co-investorsOUP (Osage University Partners)Treo Ventures, Llc
Onkos Surgical develops limb salvage and orthopedic reconstruction implants and systems for treating musculoskeletal cancer and complex orthopedic conditions.
HardwareHealthtechMedical DevicesParsippany, US
Patrick Treacy(Founder)in
Board seatStephen BlochΒ· per SEC Form D
Co-investors1315 CapitalJSD Capital, LLCSV Health Investors
BiotechResearch Triangle Park, US
Andrew Jordan(Executive Officer, Director)John Taylor(Executive Officer, Director, Promoter)Robert Tarran(Director)
BoardDonald Rose(Director)
Board seatTim ShannonΒ· per SEC Form D Β· $5M raise Β· filed Jul 2017
Truveris offers a technology platform with claims analytics and PBM (pharmacy benefit manager) oversight to reduce pharmacy benefit costs through contract optimization for employers.
Data & InfrastructureDigital HealthHealthtechSaaSNew York, US
Michael Facendola(Executive Officer)Louise Shea(Chief Pharmacy Officer)inSomak Chattopadhyay(Director)Anthony Joseph Loiacono(Executive Vice-President, Sales and Marketing)Leon Stewart Greene(Executive Vice-President, Operations)Bryan Birch(Chief Executive Officer)
Board seatStephen BlochΒ· per SEC Form D
Co-investorsMcKesson VenturesNAV.VCTribeca Venture PartnersNew Leaf Venture Partners
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.